Suppr超能文献

一项建立高分子量尿型纤溶酶原激活剂(HMW/u-PA)标准的合作研究。

A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA).

作者信息

Gaffney P J, Heath A B

机构信息

Division of Haematology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.

出版信息

Thromb Haemost. 1990 Nov 30;64(3):398-401.

PMID:2128969
Abstract

An international collaborative study involving eleven laboratories located in eight countries was undertaken to establish an International Standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA). The current International Reference Preparation (IRP code numbered 66/46) for urinary-type plasminogen activator (u-PA) or urokinase (see Nomenclature footnote) is a 66/34 molar ratio mixture of low molecular weight (LMW)--and high molecular weight (HMW)--u-PA's and is considered unsuitable as a standard for homogeneous preparations of HMW/u-PA. The putative standard for HMW/u-PA (code number, 87/594) was compared for potency in a clot lysis assay with the current IRP for u-PA (code number, 66/46) and a lyophilised preparation of single chain urinary-type plasminogen activator (SCuPA), the latter being used in the assay without prior activation by plasmin to its active two chain form (TCuPA). Both the proposed standard for HMW/u-PA (87/594) and the SCuPA compared in a statistically satisfactory manner in parallel line bioassays with the current IRP for u-PA (66/46), thus allowing potency estimates to be obtained for these two materials in relation to defined international units. Data from the eleven laboratories indicated that each ampoule of the proposed standard for HMW/u-PA contained 4,300 i.u. of activity and was stable for over 1 year at 4 degrees C. Most participants indicated that SCuPA expressed only a small amount of its activity without a prior activator step and this suggests that SCuPA assays need to be preceded by a plasmin activation step.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

一项涉及八个国家11个实验室的国际合作研究旨在建立高分子量尿型纤溶酶原激活剂(HMW/u-PA)的国际标准。目前尿型纤溶酶原激活剂(u-PA)或尿激酶(见命名注释)的国际参考制剂(IRP编号66/46)是低分子量(LMW)和高分子量(HMW)u-PA的66/34摩尔比混合物,被认为不适用于HMW/u-PA均匀制剂的标准。将HMW/u-PA的假定标准品(编号87/594)在凝块溶解试验中的效力与当前u-PA的IRP(编号66/46)以及单链尿型纤溶酶原激活剂(SCuPA)的冻干制剂进行比较,后者在试验中未经纤溶酶预先激活成其活性双链形式(TCuPA)就被使用。HMW/u-PA的提议标准品(87/594)和SCuPA在与当前u-PA的IRP(66/46)的平行线生物测定中在统计学上比较令人满意,从而可以获得这两种物质相对于规定国际单位的效力估计值。来自11个实验室的数据表明,HMW/u-PA提议标准品的每个安瓿含有4300国际单位的活性,并且在4℃下可稳定保存1年以上。大多数参与者表示,SCuPA在没有预先激活步骤的情况下仅表现出少量活性,这表明SCuPA测定需要在纤溶酶激活步骤之前进行。(摘要截短为250字)

相似文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验